Psychemedics Corporation

OTCPK:PMDI Stock Report

Market Cap: US$15.3m

Psychemedics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Brian Hullinger

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure3.1yrs
CEO ownershipn/a
Management average tenure3yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

Analysis Article • Dec 07

Psychemedics Corporation's (NASDAQ:PMD) Shares Climb 37% But Its Business Is Yet to Catch Up

The Psychemedics Corporation ( NASDAQ:PMD ) share price has done very well over the last month, posting an excellent...
Analysis Article • Jul 29

Psychemedics Corporation's (NASDAQ:PMD) Prospects Need A Boost To Lift Shares

Psychemedics Corporation's ( NASDAQ:PMD ) price-to-sales (or "P/S") ratio of 0.6x may look like a pretty appealing...
Analysis Article • Jan 08

There's Reason For Concern Over Psychemedics Corporation's (NASDAQ:PMD) Massive 28% Price Jump

Despite an already strong run, Psychemedics Corporation ( NASDAQ:PMD ) shares have been powering on, with a gain of 28...
Analysis Article • May 13

Psychemedics (NASDAQ:PMD) Is Paying Out A Dividend Of $0.07

The board of Psychemedics Corporation ( NASDAQ:PMD ) has announced that it will pay a dividend of $0.07 per share on...
Seeking Alpha • Aug 09

Psychemedics GAAP EPS of -$0.06, revenue of $6.51M

Psychemedics press release (NASDAQ:PMD): Q2 GAAP EPS of -$0.06. Revenue of $6.51M (+6.9% Y/Y).
Seeking Alpha • Apr 25

Psychemedics: 21% Sales Growth But Net Loss, Takeover Possibility, Covid Recovery Play

21% YoY revenue growth in Q4, gross margins surge 1,000 bps YoY. EPS loss of $0.29 on higher legal costs and a one-time expense. Company paid a dividend of $0.05/share in December and is evaluating options for 2022. 11% FCF yield on “normal” 2023 estimates. Management continues to evaluate “shareholder enhancement opportunities” which include a sale/merger of the company.
Seeking Alpha • Nov 18

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

29% YoY revenue growth in Q3, margins surge. EPS of $0.13 against loss per share of $0.20 in 3Q20. Worst seems to be over for the company, we expect dividends to eventually be reinstated as growth has resumed. 13x P/E, 7% FCF yield on “normal” 2023 estimates. Management continues to evaluate “shareholder enhancement opportunities” which include a potential sale/merger of the company.
Seeking Alpha • Oct 18

Psychemedics: Market Leader, 8% FCF Yield, Possible Takeover Target

Market-leading drug testing company, 30 years history, drug abuse increasing in the US. 13x P/E, 8% FCF yield on “normal” 2023 estimates. We expect resumption in dividends once financials improve. Worst seems to be over for the company and the base business is looking up. We believe the company could be a potential takeover target.
Analysis Article • May 07

We Think Psychemedics Corporation's (NASDAQ:PMD) CEO Compensation Package Needs To Be Put Under A Microscope

The results at Psychemedics Corporation ( NASDAQ:PMD ) have been quite disappointing recently and CEO Ray Kubacki bears...
Analysis Article • Mar 05

Here's Why Psychemedics (NASDAQ:PMD) Can Afford Some Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jan 11

How Much Are Psychemedics Corporation (NASDAQ:PMD) Insiders Spending On Buying Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

CEO Compensation Analysis

How has Brian Hullinger's remuneration changed compared to Psychemedics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$446kUS$375k

-US$2m

Sep 30 2024n/an/a

-US$3m

Jun 30 2024n/an/a

-US$5m

Mar 31 2024n/an/a

-US$4m

Dec 31 2023US$973kUS$126k

-US$4m

Compensation vs Market: Insufficient data to establish whether Brian's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Insufficient data to compare Brian's compensation with company performance.

CEO

Brian Hullinger (58 yo)

3.1yrs
Tenure
US$446,417
Compensation

Mr. Brian Hullinger serves as President, Chief Executive Officer and Director at Psychemedics Corporation since August 17, 2023. He served as Chief Revenue Officer at Cisive since 2018 until January 2023....

Leadership Team

NamePositionTenureCompensationOwnership
Brian Hullinger
President3.1yrsUS$446.42kno data
Daniella Mehalik
VP of Finance & Treasurer2.8yrsUS$364.56k0%
$ 0
Shannon Shoemaker
VP & Chief Revenue Officer3yrsUS$262.60k0%
$ 0
Werner Baumgartner
Founder48.7yrsno datano data
Patrick Kinney
Secretaryno datano datano data
3.0yrs
Average Tenure
39yo
Average Age

Experienced Management: PMDI's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Hullinger
President3.1yrsUS$446.42kno data
Darius Nevin
Independent Chairman4.1yrsUS$40.00k0.93%
$ 142.4k
Peter Kamin
Independent Director4.1yrsUS$40.00k9.83%
$ 1.5m
Andrew Reynolds
Independent Director4.4yrsUS$40.00k0.46%
$ 69.7k
Robyn Davis
Independent Director5.5yrsUS$40.00k0.64%
$ 97.1k
4.1yrs
Average Tenure
64yo
Average Age

Experienced Board: PMDI's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/17 23:00
End of Day Share Price 2026/06/26 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Psychemedics Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack WallaceSidoti & Company, LLC